NCT07270679
Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 31 days later.
See at-risk trials from IRCCS Azienda Ospedaliero-Universitaria di Bologna
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Primary completion pushed from Oct 2026 to Dec 2026
- Study completion pushed from Dec 3, 2026 to Feb 2027
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
To compare the mutational status of genes involved in DNA repair mechanisms in ovarian tissue fragments from women who underwent ovarian cryopreservation and completed chemotherapy treatment for lymphoma or breast cancer
Timeframe: At least 6 months after the end of chemotherapy
Secondary (1)
To compare the mutational load of altered genes between women who developed POI and those who did not after undergoing chemotherapy
Sites
1 site in 1 country
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, Bologna, Italy